Alexion Pharmaceuticals — Merger or Acquisition (October 2019)
21 slides from Alexion Pharmaceuticals's merger presentation, Oct 16, 2019
Slide 1: Alexion to Acquire Achillion Conference Call
CONFERENCE CALL OCTOBER [X], 2019 Alexion to Acquire Achillion Conference Call October 16, 2019 Exhibit 99.2
Slide 2: Acquisition of Achillion Agenda
Acquisition of achillion agenda Introduction Susan Altschuller, Ph.D., Vice President, Investor Relations Strategic Rationale Ludwig Hantson, Ph.D., Chief Executive Officer Overview of Factor D Portfolio John Orloff, M.D., Head of R&D Ludwig Hantson, Ph.D., Chief Executive Officer Closing Remarks Br
Slide 3: Forward-looking statements
This presentation contains forward-looking statements including, statements related to: the proposed acquisition of Achillion by Alexion; Alexion’s ability to create value for patients and shareholders from the acquisition of Achillion and Alexion’s ability to advance Achillion’s pipeline; Achillion
Slide 4: Strategic Rationale
Strategic Rationale Ludwig Hantson, Ph.D. Chief Executive Officer
Slide 5: Alexion to Acquire Achillion: Strategic Rationale
ALEXION TO ACQUIRE ACHILLION Strategic Rationale Further builds diversified pipeline with potential to treat additional complement-mediated diseases, creating value for patients and shareholders Strategic Rationale Development-stage biopharmaceutical company Focused on developing transformative ther
Slide 6: Financial Overview & Lead Indications
Financial Overview & Lead Indications Aradhana Sarin, M.D. Chief Strategy and Business Officer
Slide 7: Acquisition Terms & Financial Impact
Acquisition Terms & Financial Impact Financial overview Aligned With Our Disciplined Business Development Strategy Deal Terms Initial consideration of ~$930M or $6.30 per share Also acquiring $230M* cash on Achillion’s balance sheet Potential additional consideration to be paid in the form of CVRs i
Slide 8: Enhancing Treatment for PNH Patients Experiencing Clinical EVH
Enhancing Treatment for PNH Patients Experiencing Clinical EVH Lead indications <10% of C5-treated PNH patients experience clinical extravascular hemolysis (EVH) Achillion’s lead compound danicopan has demonstrated in clinical trials to work with C5 inhibition to more effectively treat PNH patients
Slide 9: Potential first-in-class treatment for C3G
Potential first-in-class treatment for C3G Lead indications Ultra-rare, chronic kidney disease caused by uncontrolled complement activation and deposition Results in devastating kidney damage Up to 50% of patients progress to kidney failure within 10 years ~70% of C3G kidney transplant patients expe
Slide 10: Overview of Factor D Portfolio
Overview of Factor D Portfolio John Orloff, M.D. Head of R&D
Slide 11: Targeting Factor D to inhibit the complement alternative pathway
Achillion: targeting factor d to inhibit the complement alternative pathway Overview of Factor D Portfolio Targeting Factor D – an upstream regulator and a key, rate-limiting enzyme of the complement alternative pathway – allows for complement inhibition Selective inhibition of the alternative pathw
Slide 12: Danicopan (ACH-4471): Addressing PNH patients with EVH
Danicopan (ACH-4471): Addressing PNH patients with EVH Overview of Factor D Portfolio Phase 2 Interim Results: Hemoglobin Improvement Compared to Baseline (g/dL) (Danicopan + Eculizumab) Ongoing open-label, multi-dose Phase 2 study of danicopan TID (3x per day) + eculizumab in PNH patients with inad
Slide 13: Danicopan (ACH-4471): First potential therapy for patients with C3G
Danicopan (ACH-4471): First potential therapy for patients with c3g Overview of Factor D Portfolio Two Ongoing Phase 2 Studies 12-Month Open-Label Phase 2 Trial 6-Month Blinded Phase 2 Trial 22 patients enrolled 13 patients enrolled Changes in Renal Biopsy Scores Reductions in Proteinuria (urine pro
Slide 14: ACH-5228: potential best-in-class oral complement inhibitor
Ach-5228: potential best-in-class oral complement inhibitor Overview of Factor D Portfolio Successful Phase 1 multiple ascending dose study 43 healthy volunteers received oral doses ranging from 40mg to 200mg BID (twice per day) for 14 days1 When dosed 120mg BID or higher, ACH-5228 achieved near com
Slide 15: Expanding to Other Alternative Pathway-mediated Rare Diseases
Expanding to Other Alternative Pathway-mediated Rare Diseases Overview of Factor D Portfolio Established scientific rationale to treat complement alternative pathway-mediated rare diseases Acquisition creates opportunity to leverage Alexion’s leading rare disease development and commercialization ca
Slide 16: Pipeline Update
Pipeline Update ACLEXion:
Slide 17: Option to Co-Develop and Commercialize Elamipretide
Option to Co-Develop and Commercialize Elamipretide Pipeline Primary Mitochondrial Myopathy (PMM) Lead indication PMM: Mitochondrial disorder characterized by debilitating muscle weakness, chronic fatigue, and exercise intolerance. Caused by mitochondrial dysfunction resulting from cardiolipin perox
Slide 18: Achillion bolsters Alexion's early and advanced clinical pipelines
ACH-5228 PNH Achillion bolsters Alexion’s early and advanced clinical pipelines Pipeline Hematology & Nephrology Metabolics Neurology FcRn TBD / Other Italicized = plans to initiate Internal Complement Programs Preclinical Early Clinical Advanced Clinical ALXN1210 QW SubQ ALXN1210 IV PNH Complement
Slide 19: Closing Remarks
Closing Remarks Ludwig Hantson, Ph.D. Chief Executive Officer
Slide 20: Aligned with our strategy to deliver long-term growth
Aligned with our strategy to deliver long-term growth Closing Build and Diversify in Rare Diseases Broaden Alexion’s portfolio with the potential to serve more patients with rare complement-mediated diseases Disciplined Business Development Transaction maintains Alexion’s financial flexibility to co
Slide 21: Alexion
ALEXION asa
Alexion Pharmaceuticals — Merger or Acquisition (October 2019) on 6ix